BFGIX
Price
$65.83
Change
+$3.11 (+4.96%)
Updated
Jun 12 closing price
Net Assets
6B
PEMGX
Price
$38.12
Change
+$0.13 (+0.34%)
Updated
Jun 12 closing price
Net Assets
24.11B
Interact to see
Advertisement

BFGIX vs PEMGX

Header iconBFGIX vs PEMGX Comparison
Open Charts BFGIX vs PEMGXBanner chart's image
BFGIX vs PEMGX Comparison Chart in %
View a ticker or compare two or three
VS
BFGIX vs. PEMGX commentary
Jun 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BFGIX is a Buy and PEMGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PEMGX has more cash in the bank: 24.1B vs. BFGIX (6B). BFGIX (0.00) and PEMGX (0.00) have matching dividends . BFGIX was incepted earlier than PEMGX: BFGIX (17 years) vs PEMGX (21 years). BFGIX (1.05) is less costly to investors than PEMGX (0.90). PEMGX is a more actively managed with annual turnover of: 13.70 vs. BFGIX (8.00). PEMGX has a lower initial minimum investment than BFGIX: PEMGX (1000) vs BFGIX (1000000). BFGIX annual gain was more profitable for investors over the last year : 29.87 vs. PEMGX (-13.56). BFGIX return over 5 years is better than : 47.87 vs. PEMGX (-2.06).
BFGIXPEMGXBFGIX / PEMGX
Total Expense Ratio1.050.90117%
Annual Report Gross Expense Ratio1.050.90117%
Fund Existence17 years21 years-
Gain YTD8.864-6.408-138%
Front LoadN/A6%-
Min. Initial Investment10000001000100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets6B24.1B25%
Annual Yield % from dividends0.000.00-
Returns for 1 year29.87-13.56-220%
Returns for 3 years82.7114.30578%
Returns for 5 years47.87-2.06-2,329%
Returns for 10 years401.8581.67492%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AKTS21.932.47
+12.69%
Aktis Oncology Inc
ACLS180.126.55
+3.77%
Axcelis Technologies
MMM158.320.41
+0.26%
3M Company
PROF6.62-0.02
-0.38%
Profound Medical Corp
NEUP4.37-0.12
-2.67%
Neuphoria Therapeutics Inc